Treatment, a set of management techniques, is specific to DSPD. It is different from treatment of insomnia, and recognizes the patients' ability to sleep well on their own schedules, while addressing the timing problem. Success, if any, may be partial; for example, a patient who normally awakens at noon may only attain a wake time of 10 or 10:30 with treatment and follow-up. Being consistent with the treatment is paramount. Before starting DSPD treatment, patients are often asked to spend at least a week sleeping regularly, without napping, at the times when the patient is most comfortable. It is important for patients to start treatment well-rested.
Non-pharmacological Techniques to shift the cycle to earlier times that do not require technology often involve gradually shifting the sleeping time earlier at a pace comfortable for the patient (
melatonin may be used as an augment here). The photopigment of the retinal
photosensitive ganglion cells,
melanopsin, is excited by light mainly in the blue portion of the visible spectrum (absorption peaks at ~480 nanometers). A formerly popular treatment,
phase delay chronotherapy, is intended to reset the circadian clock by manipulating bedtimes. It consists of going to bed two or more hours later each day for several days until the desired bedtime is reached, and it often must be repeated every few weeks or months to maintain results. Its safety is uncertain, notably because it has led to the development of
non-24-hour sleep–wake disorder, a much more severe disorder. Earlier exercise and meal times can also help promote earlier sleep times.
Pharmacological Aripiprazole (brand name Abilify) is an atypical antipsychotic that has been shown to be effective in treating DSPD by advancing sleep onset, sleep midpoint, and sleep offset at relatively low doses (0.5–1 mg),
Agomelatine works on
melatonin MT1 and MT2 receptors, alongside having antidepressant (antagonist) effects on the
5-HT2C receptor. It was used successfully in a case study of a man who acquired DSPD-like symptoms from a TBI. It is not currently approved for DSPD, and other evidence for its usage is scarce. but a decrease in exposure to light in the evening is helpful in establishing an earlier pattern. In accordance with its phase response curve (PRC), a very small dose of melatonin can also, or instead, be taken 6-8 hours before sleep onset as an aid to advancing the circadian phase; Side effects of melatonin may include sleep disturbance,
nightmares, daytime sleepiness, and depression, though the current tendency to use lower doses has decreased such complaints. Large doses of melatonin can even be counterproductive: Lewy et al. provide support to "the idea that too much melatonin may spill over onto the wrong zone of the melatonin phase-response curve." The long-term effects of melatonin administration have not been examined. In some countries, the hormone is available only by prescription or not at all. In the United States, Canada and Germany, melatonin is on the shelf of most pharmacies and herbal stores. The prescription medication
ramelteon (Rozerem) is a melatonin analogue that selectively binds to the
melatonin MT1 and MT2 receptors, which has led to the hypothesis that it may be effective in the treatment of DSPD. The effectiveness of ramelteon has been contested, with studies often finding mixed results. A review by the
US Department of Health and Human Services found little difference between melatonin and placebo for most primary and secondary sleep disorders. The one exception, where melatonin is effective, is the "circadian abnormality" DSPD. Another systematic review found inconsistent evidence for the efficacy of melatonin in treating DSPD in adults, and noted that it was difficult to draw conclusions about its efficacy because many recent studies on the subject were uncontrolled.
Modafinil (brand name Provigil) is a stimulant approved in the US for treatment of shift-work sleep disorder, which shares some characteristics with DSPD. A number of clinicians prescribe it for DSPD patients, as it may improve a sleep-deprived patient's ability to function adequately during socially desirable hours. It is generally not recommended to take modafinil after noon; modafinil is a relatively long-acting drug with a half-life of 15 hours, and taking it during the later part of the day can make it harder to fall asleep at bedtime.
Vitamin B12 was, in the 1990s, suggested as a remedy for DSPD, and is still recommended by some sources. Several case reports were published. However, a review for the
American Academy of Sleep Medicine in 2007 concluded that no benefit was seen from this treatment. ==Prognosis==